- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|BMS986195 | branebrutinib (proposed INN) | Example 223 [US20160115126A1]|
|BMS-986195 (branebrutinib) is a potent, covalent, irreversible inhibitor of the TEC family non-receptor tyrosine kinase, Bruton's tyrosine kinase (BTK) . BTK is essential in antigen-dependent B-cell signaling and function, and is a therapeutic target for oncology and rheumatic diseases. BMS-986195 is a clinical lead for the treatment of rheumatoid arthritis, as claimed in Bristol-Myers Squibb's patent US20160115126A1 (Example 223) .
Branebrutinib appears to be a 'pseudo' INN, that uses the -tinib INN stem for tyrosine kinase inhibitors, but has not (yet) been submitted to the World Health Organisation for ratification.
|GtoPdb PubChem SID||363894163|
|Search Google for chemical match using the InChIKey||VJPPLCNBDLZIFG-ZDUSSCGKSA-N|
|Search Google for chemicals with the same backbone||VJPPLCNBDLZIFG|
|Search UniChem for chemical match using the InChIKey||VJPPLCNBDLZIFG-ZDUSSCGKSA-N|
|Search UniChem for chemicals with the same backbone||VJPPLCNBDLZIFG|